Sei Investments CO Palatin Technologies Inc Transaction History

Sei Investments CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$0.38 - $0.78 $93,112 - $191,125	-245,033 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$0.47 - $0.64 $68,933 - $93,866	146,667 Added 149.1%	245,033 $116,000
Q2 2020 Aug 17, 2020	BUY	$0.41 - $0.73 $30,795 - $54,831	75,112 Added 323.01%	98,366 $50,000
Q2 2020 Aug 11, 2020	SELL	$0.41 - $0.73 $30,795 - $54,831	-75,112 Reduced 76.36%	23,254 $18,000
Q1 2020 May 14, 2020	BUY	$0.36 - $0.79 $27,040 - $59,338	75,112 Added 323.01%	98,366 $42,000
Q4 2019 Feb 06, 2020	BUY	$0.75 - $0.89 $17,440 - $20,696	23,254 New	23,254 $18,000
Q1 2019 May 15, 2019	SELL	$0.67 - $1.01 $15,953 - $24,049	-23,811 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$0.88 - $1.1 $5,993 - $7,492	6,811 Added 40.06%	23,811 $24,000
Q2 2018 Aug 03, 2018	SELL	$0.91 - $1.45 $1,395 - $2,224	-1,534 Reduced 8.28%	17,000 $16,000
Q1 2018 May 11, 2018	BUY	$0.84 - $1.18 $350 - $492	417 Added 2.3%	18,534 $21,000
Q4 2017 Feb 08, 2018	BUY	$0.68 - $1.0 $759 - $1,117	1,117 Added 6.57%	18,117 $16,000
Q3 2017 Nov 06, 2017	BUY	$0.39 - $0.66 $6,630 - $11,220	17,000	17,000 $11,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $10.3M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.